A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

NCT00424476 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

865

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Placebo
DRUG: Belimumab 1 mg/kg
DRUG: Belimumab 10 mg/kg

Sponsor

Human Genome Sciences Inc.

Collaborators

[object Object]